This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 699118
Download Presentation The PPT/PDF document "Next-Gen Psoriasis Therapies:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Next-Gen Psoriasis Therapies:Slide2
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide3
Psoriasis BasicsSlide4
Pathogenesis of PsoriasisSlide5
Pathogenesis of Psoriasis
TNF-
αSlide6
Pathogenesis of Psoriasis
InterleukinsSlide7
Targeted Agents for PsoriasisSlide8
PDE4 InhibitorSlide9
IL-17 and IL-17 Receptor BlockersSlide10
IL-23 BlockersSlide11
JAK InhibitorsSlide12
Psoriasis Treatment and Its Effect on Outcomes: EfficacySlide13
Safety Considerations
IL-17 InhibitionSlide14
Safety Considerations
IL-12 and IL-23 InhibitionSlide15
Newer Biologics Have Less Toxicity Compared With Older Systemic AgentsSlide16
Who Would Benefit From Newer Targeted Agents?Slide17
Who Would Benefit From Newer Targeted Agents? (cont)Slide18
Who Would Benefit From Newer Targeted Agents? (cont)Slide19
Who Would Benefit From Newer Targeted Agents? (cont)Slide20
Who Would Benefit From Newer Targeted Agents? (cont)Slide21
Psoriasis and Cardiovascular DiseaseSlide22
Other Potential ConsiderationsSlide23
Other Potential Considerations (cont)Slide24
Concluding RemarksSlide25
AbbreviationsSlide26
Abbreviations (cont)